This clinical trial is focused on studying Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures. The trial will evaluate a treatment called BHV-7000, which is a prolonged-release tablet developed by Biohaven Therapeutics Ltd. The purpose of the study is to compare the effectiveness of BHV-7000 to a placebo when used as an additional therapy for people with this type of epilepsy.

Participants in the study will receive either the BHV-7000 tablet or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The trial will include an open-label extension, which means that after the initial phase, all participants may have the opportunity to receive BHV-7000 if they choose to continue. The study will last for a period of up to 72 weeks.

The main goal is to observe the time it takes for participants to experience a second day with a generalized tonic-clonic seizure during the double-blind phase. Additionally, the study will assess the safety and tolerability of BHV-7000 by monitoring any side effects or adverse events that occur. This trial aims to provide valuable information on the potential benefits and risks of using BHV-7000 as a treatment option for individuals with this form of epilepsy.